Login / Signup

Total Chemical Synthesis of Palmitoyl-Conjugated Insulin.

Mengjie LiuQingyang LiCarlie DelaineHongkang WuYanni ArsenakisBarbara F WhiteBriony E ForbesChaitra ChandrashekarMohammed Akhter Hossain
Published in: ACS omega (2023)
Commercially available insulins are manufactured by recombinant methods for the treatment of diabetes. Long-acting insulin drugs (e.g., detemir and degludec) are obtained by fatty acid conjugation at LysB29 ε-amine of insulin via acid-amide coupling. There are three amine groups in insulin, and they all react with fatty acids in alkaline conditions. Due to the lack of selectivity, such conjugation reactions produce non-desired byproducts. We designed and chemically synthesized a novel thiol-insulin scaffold (CysB 29 -insulin II ), by replacing the Lys B29 residue in insulin with the Cys B29 residue. Then, we conjugated a fatty acid moiety (palmitic acid, C16) to CysB 29 -insulin II by a highly efficient and selective thiol-maleimide conjugation reaction. We obtained the target peptide (palmitoyl-insulin) rapidly within 5 min without significant byproducts. The palmitoyl-insulin is shown to be structurally similar to insulin and biologically active both in vitro and in vivo. Importantly, unlike native insulin, palmitoyl-insulin is slow and long-acting.
Keyphrases
  • type diabetes
  • glycemic control
  • fatty acid
  • highly efficient
  • metabolic syndrome
  • cardiovascular disease
  • drinking water
  • drug induced
  • ionic liquid